- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Nuvectis Pharma auf Konferenz von H.C. Wainwright: Pipeline und Cash-Position im Fokus | 1 | Investing.com Deutsch | ||
| 11.09. | Nuvectis setzt auf Faktor-B-Inhibitor NXP100 im Wettbewerb mit Novartis | 10 | Investing.com Deutsch | ||
| NUVECTIS PHARMA Aktie jetzt für 0€ handeln | |||||
| 01.09. | Lucid Capital Markets initiates Nuvectis Pharma stock with buy rating | 1 | Investing.com | ||
| 21.08. | Nuvectis Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.08. | Nuvectis Pharma Q2 Loss Widens From Higher Costs, Shares Down | 2 | RTTNews | ||
| 04.08. | Nuvectis Pharma, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 04.08. | Nuvectis Pharma, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 04.08. | Nuvectis Pharma, Inc.: Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights | 447 | GlobeNewswire (Europe) | Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group ("Haisco"), transforming the company into a late-stage clinical... ► Artikel lesen | |
| 23.07. | China approves Nuvectis' ciprocopan for blood disorder PNH | 1 | Investing.com | ||
| 23.07. | China erteilt Zulassung für Nuvectis-Medikament Ciprocopan zur Behandlung der Blutkrankheit PNH | 1 | Investing.com Deutsch | ||
| 23.07. | Nuvectis Pharma, Inc.: Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors | 312 | GlobeNewswire (Europe) | First global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy and safety data from Haisco's broad completed clinical development program... ► Artikel lesen | |
| 14.07. | Wall Street Wire: StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data | 843 | Newsfile | New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease player following its June licensing deal with Haisco... ► Artikel lesen | |
| 08.07. | Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High? | 2 | Zacks | ||
| 30.06. | Nuvectis Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.06. | Kapitalerhöhung mit hohem Abschlag: Nuvectis Pharma Aktie bricht um 25 % ein | 3 | Investing.com Deutsch | ||
| 30.06. | Nuvectis Pharma shares slide 19% on pricing of $100M stock offering | 1 | Seeking Alpha | ||
| 30.06. | Nuvectis Pharma prices $100 million public offering at $20/share | 3 | Investing.com | ||
| 30.06. | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock | 2 | GlobeNewswire (USA) | ||
| 29.06. | Nuvectis Pharma announces public share offering to support drug programs | 1 | Seeking Alpha | ||
| 29.06. | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 8,670 | -0,46 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| INOVIO PHARMACEUTICALS | 1,076 | +1,61 % | Inovio vor entscheidender FDA-Zulassung: Markteinführung von INO-3107 rückt näher | ||
| INFLARX | 1,842 | +2,39 % | Klinische Daten geben InflaRx NV neuen Schub: Der Weg über 2 EUR | ||
| INTELLIA THERAPEUTICS | 10,360 | -3,00 % | Cathie Wood's ARK sells Twist Bioscience stock, buys more Intellia | ||
| EDITAS MEDICINE | 2,370 | 0,00 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,385 | -7,45 % | Mehr als 98% bleiben draußen: Warum Roche, Denali und NurExone neue Wege ins Nervensystem suchen | ||
| IBIO | 1,109 | +1,37 % | iBio stock initiated at buy by H.C. Wainwright with $7 target | ||
| GERON | 1,159 | +0,39 % | Geron Corporation: Geron Announces Appointment of Chinmaya Rath as Chief Business Officer | FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| IMMUNITYBIO | 7,380 | +0,14 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 7,525 | -2,15 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 3,280 | -9,17 % | Myriad Genetics, Inc.: Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial | SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been... ► Artikel lesen | |
| MANNKIND | 3,073 | -0,68 % | Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 | ||
| GINKGO BIOWORKS | 6,842 | +0,23 % | Ginkgo Bioworks To Build Autonomous Lab At Novo's New U.S. R&D Site In Waltham | ||
| IMMUNIC | 9,010 | +0,20 % | EQS-News: Immunic AG: Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
02.09.2026 / 12:30 CET/CEST
The issuer... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 6,020 | -1,55 % | Emergent BioSolutions: Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility |
NUVECTIS PHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +3,11 % bei einem Aktienkurs von 22,045 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NUVECTIS PHARMA INC finden Sie auf Wallstreet Online.